Chemotherapy‐induced neuropathy

@article{Windebank2008ChemotherapyinducedN,
  title={Chemotherapy‐induced neuropathy},
  author={Anthony J Windebank and W Grisold},
  journal={Journal of the Peripheral Nervous System},
  year={2008},
  volume={13}
}
Abstract  Neurotoxic side effects of cancer therapy are second in frequency to hematological toxicity. Unlike hematological side effects that can be treated with hematopoietic growth factors, neuropathies cannot be treated and protective treatment strategies have not been effective. For the neurologist, the diagnosis of a toxic neuropathy is primarily based on the case history, the clinical and electrophysiological findings, and knowledge of the pattern of neuropathy associated with specific… Expand

Paper Mentions

Interventional Clinical Trial
Paclitaxel is a chemotherapy drug that is used to treat breast cancer, one of the most common cancers. It causes two side effects very often - hair-loss and numbness. Until recently… Expand
ConditionsChemotherapy-induced Peripheral Neuropathy (CIPN)
InterventionDevice
Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.
TLDR
Peripheral neuropathies induced by chemotherapy (CIPN) are an increasingly frequent problem, and concepts of rehabilitation need to be implemented to improve the patients' functions and quality of life. Expand
Animal models of chemotherapy-evoked painful peripheral neuropathies
TLDR
Improved understanding of the pathophysiology of chemotherapy-induced neurotoxicity need for animal models is clinically relevant and will assist in the development of future neuroprotective strategies and also in the design of novel chemotherapies with improved toxicity profiles. Expand
Chemotherapy-Induced Peripheral Neuropathy
TLDR
Onset of symptoms is variable usually few weeks to months after the therapy is started, and can be severe enough for patient to opt out of live saving chemotherapy. Expand
Chemotherapy-induced peripheral neuropathy.
  • J. Fehrenbacher
  • Medicine
  • Progress in molecular biology and translational science
  • 2015
TLDR
There are subtle differences in the clinical presentation of CIPN, suggesting that each class of drugs might induce neuropathy via different mechanisms, and further research is necessary to identify the specific mechanisms by which eachclass of chemotherapeutics induces neuropathy. Expand
Chemotherapy-induced peripheral neurotoxicity
TLDR
The mechanistic and clinical aspects of this unpredictable condition are considered, along with the controversial aspects of CIPN, including the onset mechanisms associated with the different drug types, assessment of the patient's condition, and the current status of neuroprotection and treatment options. Expand
[Chemotherapy-induced peripheral neuropathy: an unresolved issue].
INTRODUCTION Chemotherapy-induced peripheral neuropathy (CIPN) is the most prevalent neurological complication of cancer treatment, affecting a third of all patients who undergo chemotherapy. CIPNExpand
Chemotherapy-induced peripheral neuropathy
TLDR
The present review highlighted the current view of peripheral neuropathy during chemotherapeutic approaches by searching the electronic database PubMed for pre-clinically and clinically controlled trials reporting neuropathy of adverse effects, a result of chemotherapy in cancer patients. Expand
Emerging Trends in Understanding Chemotherapy-Induced Peripheral Neuropathy
TLDR
The aim of this review is to describe the clinical features of CIPN and to summarize the recent trends in understanding its pathophysiology. Expand
Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review
TLDR
These long-term effects are associated with comorbidities such as depression, insomnia, falls and decreases of health-related quality of life in cancer patients and survivors and it is noteworthy that these long- term effects remain poorly studied, and only limited data are available. Expand
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
TLDR
A better understanding of the risk factors and underlying mechanisms of CIPN is needed to develop effective preventive and therapeutic strategies and the neurotoxicity mechanisms of the most common antineoplastic agents are reviewed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 215 REFERENCES
Management of chemotherapy-induced peripheral neuropathy
TLDR
Basic and clinical researchers have begun to investigate therapy to prevent neurotoxic injury, and preliminary studies have shown promise for some agents including glutamine, glutathione, vitamin E, acetyl-L-carnitine, calcium, and magnesium infusions. Expand
Neurological complications of cancer chemotherapy
TLDR
Magnetic resonance diffusion-weighted and fluid-attenuated inversion-recovery imaging are useful in demonstrating chemotherapy-induced central nervous system lesions, which remain a major limitation of many drugs used in cancer patients. Expand
The pathophysiology of oxaliplatin-induced neurotoxicity.
TLDR
Recent developments in clinical rating scales and novel neurophysiological methods for the clinical investigation of chemotherapy-induced neurotoxicity will be focused on and it will be highlighted how such methods may prove useful to study the neurological effects of chemotherapy. Expand
Peripheral neuropathy induced by microtubule-stabilizing agents.
  • James J. Lee, S. Swain
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
Although there have been several small clinical trials with neuroprotective agents, early recognition and supportive care are the best approaches for prevention and management of MTSA-induced neuropathy. Expand
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.
TLDR
Although there is no indication at the moment that a common cellular mechanism induces both the acute and the cumulative neurotoxicity of oxaliplatin, controlled clinical trials are currently underway to establish the value of Na(+) channel blockade against both acute and cumulative oxaliplant neurotoxicities. Expand
Oxaliplatin-safety profile: neurotoxicity.
TLDR
The predictability of neurotoxicity associated with oxaliplatin-based therapy should allow patients and doctors to develop strategies to manage this side effect in view of the individual patient's clinical situation. Expand
Paclitaxel-induced neuropathy.
TLDR
Using 3-weekly 3-hour infusions of paclitaxel, dose-limiting neurotoxicity can be expected in patients treated with 250 mg/m2 or more each cycle, and follow-up data of 12 patients after discontinuation of pac litaxel therapy showed that pac Litaxel-induced neuropathy is at least partially reversible. Expand
Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil
TLDR
Two patients treated in a phase I trial of oral 5-FU, leucovorin and eniluracil, an inhibitor of dihydropyrimidine dehydrogenase (DPD), developed delayed onset symptoms of unsteady gait and reduced sensation in the legs, and it is likely that5-FU or its active metabolites were contributing factors to the peripheral neuropathy. Expand
Suramin-induced neuropathy in an animal model
TLDR
Suramin induced a length, dose and time-dependent axonal sensorimotor polyneuropathy associated with axonal degeneration, atrophy, and accumulation of glycolipid lysosomal inclusions in rats. Expand
Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients.
TLDR
Hematopoietic toxicity of high-dose carboplatin chemotherapy can be tolerated by most of the patients, but careful monitoring of neuro- and, especially, ototoxicity should be planned. Expand
...
1
2
3
4
5
...